
InflaRx (IFRX) Stock Forecast & Price Target
InflaRx (IFRX) Analyst Ratings
Bulls say
InflaRx NV is positioned positively due to promising clinical results from its lead product candidate, vilobelimab, which has shown a significant 23.9% reduction in 28-day all-cause mortality, indicating strong efficacy in patient survival. The therapy's ability to reduce the need for corticosteroids and facilitate corticosteroid-free treatment in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) emphasizes its potential for practical application and demand. Additionally, post hoc analyses demonstrating substantial placebo-adjusted reductions in disease metrics further validate the therapeutic benefits of vilobelimab, supporting a favorable outlook for the company’s future performance and market position.
Bears say
InflaRx NV is currently experiencing depressed forward multiples, attributed primarily to prevailing market volatility. The company's cash burn remains a significant concern, as it may be heavily influenced by the stage of its development programs, with potential offsets from partner or collaborative revenue yet to materialize. Additionally, there is a lack of valuation assigned to commercial sales of GOHIBIC, as it is not recognized as a growth stage asset, contributing to projections of revenue generation that have largely remained stagnant.
This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.
InflaRx (IFRX) Analyst Forecast & Price Prediction
Start investing in InflaRx (IFRX)
Order type
Buy in
Order amount
Est. shares
0 shares